Lyra Therapeutics Statistics
Want to see LYRA full AI Analyst Report?
Lyra Therapeutics (LYRA) Stock Statistics & Valuation Metrics
Total Valuation
Lyra Therapeutics has a market cap or net worth of $337.23K. The enterprise value is $19.83M.
- Market Cap
- $337.23K
- Enterprise Value
- $19.83M
Share Statistics
Lyra Therapeutics has 1,774,882 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,774,882
- Owned by Insiders
- 91.65%
- Owned by Institutions
- 6.04%
Financial Efficiency
Lyra Therapeutics’s return on equity (ROE) is 2.70 and return on invested capital (ROIC) is -98.78%.
- Return on Equity (ROE)
- 2.70
- Return on Assets (ROA)
- -0.80
- Return on Invested Capital (ROIC)
- -98.78%
- Return on Capital Employed (ROCE)
- -1.17
- Revenue Per Employee
- 14.74K
- Profits Per Employee
- -1.07M
- Employee Count
- 27
- Asset Turnover
- 0.01
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Lyra Therapeutics is -0.01. Lyra Therapeutics’s PEG ratio is 0.00.
- PE Ratio
- -0.01
- PS Ratio
- 1.57
- PB Ratio
- -0.28
- Price to FCF
- -0.02
- Price to Operating Cash Flow
- -0.15
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Lyra Therapeutics had revenue of 398.00K and earned -28.92M in profits. Earnings per share was -18.62.
- Revenue
- 398.00K
- Gross Profit
- 398.00K
- Operating Income
- -31.02M
- Pretax Income
- -28.91M
- Net Income
- -28.92M
- EBITDA
- -29.09M
- Earnings Per Share (EPS)
- -18.62
Cash Flow
In the last 12 months, operating cash flow was -28.86M and capital expenditures -116,000, giving a free cash flow of -28.98M billion.
- Operating Cash Flow
- -28.86M
- Free Cash Flow
- -28.98M
- Free Cash Flow per Share
- -1.30
Dividends & Yields
Lyra Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -5970.14%
- Earnings Yield
- -690.20%
Stock Price Statistics
- Beta
- 4.99
- 52-Week Price Change
- -95.10%
- 50-Day Moving Average
- 0.18
- 200-Day Moving Average
- 0.62
- Relative Strength Index (RSI)
- 50.09
- Average Volume (3m)
- 1,433
Important Dates
Lyra Therapeutics upcoming earnings date is Nov 17, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 11, 2026
- Next Earnings Date
- Nov 17, 2026
- Ex-Dividend Date
- ―
Financial Position
Lyra Therapeutics as a current ratio of 1.71, with Debt / Equity ratio of -282.35%
- Current Ratio
- 1.71
- Quick Ratio
- 1.71
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.49
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Lyra Therapeutics has paid 11.00K in taxes.
- Income Tax
- 11.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Lyra Therapeutics EV to EBITDA ratio is -0.74, with an EV/FCF ratio of -0.73.
- EV to Sales
- 68.39
- EV to EBITDA
- -0.74
- EV to Free Cash Flow
- -0.73
- EV to Operating Cash Flow
- -0.73
Balance Sheet
Lyra Therapeutics has $15.89M in cash and marketable securities with $30.26M in debt, giving a net cash position of -$14.37M billion.
- Cash & Marketable Securities
- $15.89M
- Total Debt
- $30.26M
- Net Cash
- -$14.37M
- Net Cash Per Share
- -$8.09
- Tangible Book Value Per Share
- -$0.69
Margins
Gross margin is 100.00%, with operating margin of -10316.74%, and net profit margin of -9475.35%.
- Gross Margin
- 100.00%
- Operating Margin
- -10316.74%
- Pretax Margin
- -9472.09%
- Net Profit Margin
- -9475.35%
- EBITDA Margin
- -9302.33%
- EBIT Margin
- -9454.42%
Analyst Forecast
The average price target for Lyra Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -74.05%
- EPS Growth Forecast
- 73.08%
Scores
- Smart Score
- ―
- AI Score
- 41
